Camurus AB (CAMRF) reports a 52% revenue increase, strategic licensing with Eli Lilly, and EU approval of Oczyesa, despite currency challenges and market hurdles.

"Successful second quarter for Camurus" Summary second quarter 2025 April - June Total revenues grew 52% (65% at CER1) to SEK 676 (445) million Sales of Buvidal® increased 17% (26% at CER1) to SEK ...

Access Camurus AB stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.

Camurus, an international, science-led biopharmaceutical company, announced that the European Commission (EC) has granted Oczyesa, octreotide subcutaneous depot, marketing authorization for the ...

Camurus’ Oczyesa receives European marketing authorization for treatment of acromegaly: Lund, Sweden Wednesday, July 2, 2025, 17:00 Hrs [IST] Camurus, an international, science- ...

About Camurus Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with ...

Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and ...

Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult ...

Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult ...